CARDIOVASCULAR EFFECTS OF INDACATEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
https://doi.org/10.18093/0869-0189-2016-26-5-570-577
Abstract
The aim of this study was to investigate cardiovascular effects of the inhaled betaagonist indacaterol in COPD patients. Methods. In this prospective reallife nonrandomized study, 25 patients with moderate COPD were treated with indacaterol for 3 months. Lung function testing, echocardiography, measurements of arterial stiffness, pulse wave velocity, heart rate variability and compliance were done. Results. Tendencies to the heart size reduction, decrease in the pulmonary artery pressure, improvement in the heart contractility and autonomous functions were seen after 3 months of the therapy. The lung function parameters did not change reliably. These changes were more significant in compliant patients (18 of 25). Conclusions. Therapy of COPD patients with indacaterol 150 mg daily improved the cardiovascular status.
About the Authors
N. Sh. Zagidullin
Bashkir State Medical University, Healthcare Ministry of Russia: 3, Lenina str., Ufa, 450000, Bashkortostan Republic
Russian Federation
MD, Professor at Department of Propaedeutics of Internal Diseases
Russian Federation
MD, Professor at Department of Propaedeutics of Internal Diseases
Y. F. Safina
Bashkir State Medical University, Healthcare Ministry of Russia: 3, Lenina str., Ufa, 450000, Bashkortostan Republic
Russian Federation
Resident Physician at Department of Propaedeutics of Internal Diseases
Russian Federation
Resident Physician at Department of Propaedeutics of Internal Diseases
R. H. Zulkarneev
Bashkir State Medical University, Healthcare Ministry of Russia: 3, Lenina str., Ufa, 450000, Bashkortostan Republic
Russian Federation
MD, Professor at Department of Propaedeutics of Internal Diseases
Russian Federation
MD, Professor at Department of Propaedeutics of Internal Diseases
Y. G. Aznabaeva
Bashkir State Medical University, Healthcare Ministry of Russia: 3, Lenina str., Ufa, 450000, Bashkortostan Republic
Russian Federation
PhD, Associate Professor at Department of Propaedeutics of Internal Diseases
Russian Federation
PhD, Associate Professor at Department of Propaedeutics of Internal Diseases
G. M. Nurtdinova
Bashkir State Medical University, Healthcare Ministry of Russia: 3, Lenina str., Ufa, 450000, Bashkortostan Republic
Russian Federation
PhD, Associate Professor at Department of Propaedeutics of Internal Diseases
Russian Federation
PhD, Associate Professor at Department of Propaedeutics of Internal Diseases
Sh. Z. Zagidullin
Bashkir State Medical University, Healthcare Ministry of Russia: 3, Lenina str., Ufa, 450000, Bashkortostan Republic
Russian Federation
MD, Professor, Head of Department of Propaedeutics of Internal Diseases
Russian Federation
MD, Professor, Head of Department of Propaedeutics of Internal Diseases
References
1. Global Initiative for Chronic Obstructive Lung Disease (2013) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Available from www.goldcopd.com
2. Beeh K.M., Beier J. Indacaterol: a new once daily long-acting beta2-adrenoceptor agonist. Core Evidence. 2009; 4: 37–41.
3. Lange P., Mogelvang R., Marott J.L. et al. Cardiovascular morbidity in COPD: a study of the general population. COPD. 2010; 7: 5–10.
4. Konecny T., Park J.Y., Somers K.R. et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am. J. Cardiol. 2014; 114 (2): 272–277.
5. Zulkarneev R., 5. Zagidullin N., Abdrahmanova G. et al. Ivabradine prevents heart rate acceleration in patients with chronic obstructive pulmonary disease and coronary heart disease after salbutamol inhalation. Pharmaceuticals. 2012; 5 (4): 398–404.
6. Hanrahan J.P., Grogan D.R., Baumgartner R.A. et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long acting beta2 agonists arfor moterol and salmeterol. Medicine (Baltimore). 2008; 87 (6): 319–328.
7. Karvandi M., Piranfar M.A., Ghaffaripour M. et al. An alternative method for perioperative estimation of pulmonary artery systolic pressure by echocardiography. Shiraz E$Med. J. 2007; 8 (4): 174–182.
8. Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hyper tension. Am. J. Respir. Crit. Care Med. 2006; 174 (9): 1034–1041.
9. Curkendall S.M., DeLuise C., Jones J.K. et al. Cardio vascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular dis ease in COPD patients. Ann. Epidemiol. 2006; 16: 63–70.
10. Schneider C., Bothner U, Jick S.S., Meier C.R. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur. J. Epidemiol. 2010; 25 (4): 253–260.
11. Sanduzzi A., Balbo P., Candoli P. et al. COPD: adherence to therapy. Multidiscip. Respir. Med. 2014; 9: 60.
12. Rossi A., Polese G. Indecaterol: a comprehensive review. Intern. J. COPD. 2013; 8: 353–363.
13. Avdeev S.N. Onbrez Breezhaler: actual issues. Consilium Medicum 2012; 14 (3): 79–86 (in Russian).
14. Buhl R., Dunn L.J., Disdier C. et al. Intensity study investigators Blinded 12 week comparison of once daily indacaterol and tiotropium in COPD. Eur. Respir. J. 2011; 38: 797–803.
15. Kerwin E., Hébert J., Gallagher N. et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 2012; 40: 1106–1014.
16. Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once daily long acting inhaled b2 agonist indacaterol versus twice daily formoterol in COPD. Thorax. 2010; 65: 473–479.
17. Kornmann O., Dahl R., Centanni S. et al. INLIGHT 2 (Indacaterol Efficacy Evaluation Using 150 μg Doses with COPD Patients) study investigators. Once daily indacaterol versus twice daily salmeterol for COPD: a placebo controlled comparison. Eur. Respir. J. 2011; 37: 273–279.
18. Worth H., Fan Chung K., Felser K. et al. Cardio and cere brovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir. Med. 2011; 105: 571–579.
Review
For citations:
Zagidullin N.Sh., Safina Y.F., Zulkarneev R.H., Aznabaeva Y.G., Nurtdinova G.M., Zagidullin Sh.Z. CARDIOVASCULAR EFFECTS OF INDACATEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. PULMONOLOGIYA. 2016;26(5):570-577. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-5-570-577
Views:
647
Email this article 